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ABSTRACT
Background: Other than the UK, The Netherlands has no formal thresh-
old for cost-per-QALY values deﬁned yet. For example, a cutoff value at
€20,000 per QALY is sometimes mentioned in various discussions,
however it has no formal status at all. Yet, since 2005, all new innovative
do have to go through a cost-effectiveness evaluation though, with the
assessment being focused on the methodology rather than on the exact
cost-per-QALY outcome.
Objective: Our objective was to estimate the potential impacts on Dutch
drug expenditures had a formal threshold been applied in recent years.
Methods: We analyzed national Dutch prescription data for the period
2005–2007, with respect to the costs of speciﬁc newly introduced drugs
with reported positive cost-effectiveness ratios. Various threshold values
were investigated.
Results: In particular, our analysis suggests that modest, though annually
increasing, reductions in Dutch drug expenditures could have been
achieved in the recent period 2005–2007 if a threshold for cost-
effectiveness at, for example, €20,000 per QALY been applied in The
Netherlands. At thresholds of €0 and €20,000 estimated reductions in
drug expenditures reﬂect approximately 0.25% of total Dutch drug expen-
ditures and for thresholds of €50,000 and €80,000 this is only 0.01%.
Conclusions: Modest reductions in drug expenditures can be achieved if a
formal threshold would be applied in The Netherlands. Potential reduc-
tions may be expected to increase in next years as expenditures for listed
drugs increase further and new drugs become listed. Finally, we argue that
for optimal and fair allocation of resources the in the health-care sector,
application of a straightforward threshold is eminent and should not be
postponed anymore.
Keywords: budget impact analysis, cost-effectiveness analysis, pharmacy,
The Netherlands.
Introduction
Since January 2005, one of the criteria for enlisting new drugs
within the Dutch Outpatient Drugs Reimbursement System
(“Geneesmiddelenvergoedingssysteem” [GVS]) relates to cost-
effectiveness. In the assessment process by the Dutch Foundation
for Health Care Insurance (“College voor Zorgverzekeringen”
[CVZ]), this criteria comes next to therapeutic value and cost
consequence [1,2]. Cost-effectiveness is not considered for those
drugs without added value, which are either clustered and reim-
bursed at maximally the cluster reference price or—in the
absence of possible clustering—remain unreimbursed. However,
the cost-effectiveness criteria explicitly functions as a hurdle for
reimbursement for those drugs that have proven added therapeu-
tic value and are predicted to confer extra costs to the health-care
system. Examples of drugs that were considered of added thera-
peutic value, yet failed the cost-effectiveness criteria are ivabra-
dine for the treatment of angina pectoris and the 4-valent human
papilloma virus (HPV) vaccine for the prevention of cervical
cancer. Information on such individual drugs can be found on the
CVZ website, those subpages hosting the reports of the Commit-
tee Pharmaceutical Help (“Commissie Farmaceutische Hulp”
[CFH]).
Internationally, The Netherlands are not unique in applying a
cost-effectiveness criteria for new innovative drugs. For example,
the United Kingdom’s National Institute for Health and Clinical
Excellence (NICE) and similar agencies elsewhere apply similar
criteria [3]. Often, to judge cost-effectiveness of a new drug, a
threshold is deﬁned for maximum acceptable costs per quality
adjusted life year (QALY). Notably, NICE applies £30,000 per
QALY, whereas other countries may apply US$50,000 or
€50,000 [3,4]. Strikingly, The Netherlands lack such a formal
cost-effectiveness threshold, and evaluations of the cost-
effectiveness threshold are done solely on the basis of the quality
of the cost-effectiveness analysis supplied by the manufacturer,
rather than on the actual costs per QALY estimated for the new
drug. For example, the 4-valent HPV-vaccine was denied reim-
bursement within the Dutch Drug Reimbursement System on the
basis of criticism on the economic model underlying the cost-
effectiveness estimates, regarding aspects such as the time
horizon for analysis, the assumed duration of protection and face
validity of the model outcomes [1]. For judging the quality of
cost-effectiveness models in the framework of reimbursement
decisions, Dutch guidelines for the topic have been designed.
Ergo, if in the Dutch assessment procedure of a new innova-
tive drug the cost-effectiveness analysis supplied by the manufac-
turer is considered of good quality, reimbursement will
principally not be denied on the basis of cost-effectiveness,
despite potentially relatively high cost-per-QALY values.
Notably, two recent positive decisions on reimbursement
involved cost-per-QALY performance in the range €80,000–
90,000 (dasatinib for leukemia and sitagliptine for diabetes) [1],
values that would be considered beyond the threshold in any
country that has such a threshold formally deﬁned. In The Neth-
erlands, no formal threshold exists despite that some efforts to
achieve a deﬁnition have been attempted. In particular, in the
1990s, a threshold of €20,000 per life-year gained has already
been mentioned and has actually been applied within the frame-
work of labeling patients with elevated cholesterol levels eligible
for treatment with statins [5]. Since then, €20,000 per life-year
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gained or QALY has certainly been mentioned in discussions on
rationing; however, it has never become a formal threshold for
cost-effectiveness in The Netherlands. More recently the
Council for Care & Public Health (“Raad voor Zorg & Volks-
gezondheid”) derived a threshold based on various criteria,
inclusive the country’s gross domestic product (GDP) per capita
[6]. In line with the World Health Organization, it was consid-
ered that two to three times GDP per capita would reﬂect an
acceptable cost-per-QALY threshold [7]. In particular, for the
Dutch situation, this would translate into a threshold for cost-
effectiveness at approximately €80,000 per QALY. Again, this
threshold has been discussed in decision-making forums;
however, it never achieved the status of a formal cost-
effectiveness threshold. Application of, for example, the thresh-
old speciﬁed by NICE to the Dutch situation is no valid option
either. Notably, cost-effectiveness thresholds differ per country.
Obviously, GDPs per capita vary over countries. One further
plausible reason for differing thresholds is that guidelines for the
conduct of pharmacoeconomic research differ per country [8].
For example, the Dutch guidelines prescribe the use of a societal
perspective; whereas, the UK favors the National Health Ser-
vice’s perspective. The societal perspective allows the inclusion
of a much broader spectrum of beneﬁts and savings of the drug
under consideration, which would possibly justify a lower
threshold within the societal perspective.
Quantiﬁcation of the Potential Effects
of Thresholds
With the deﬁnition of a formal Dutch cost-effectiveness threshold
still pending, an interesting question pops up regarding the ﬁnan-
cial consequences for the drug budget if since January 1, 2005 a
threshold would strictly have been applied, regardless of its exact
quantiﬁcation. Deﬁnition and strict application of a cost-per-
QALY threshold for the Dutch situation would obviously have
limited the budget impacts of new drugs in recent years, as some
drugs would have been denied based on the cost-per-QALY per-
formance. Here, we examine these consequences based on esti-
mated cost-per-QALY (or per life-year gained if per QALY was
not available) ﬁgures and drug utilization during the period
2005–2007. Notably, we investigate the drug costs per year for
speciﬁc drugs at three different thresholds: €20,000, €80,000 and
€50,000 per QALY (or life-year gained). Both former ﬁgures have
been mentioned in the Dutch decision-making context, the latter
reﬂects their midpoint and is in accordance with some other
countries’ thresholds [8]. Additionally, we investigate a theoreti-
cal threshold of €0 per QALY; i.e., no extra costs are accepted for
the achieved health gains of new drugs; i.e., cost savings would
be required.
For our analysis, drug utilization was taken from national
ﬁgures available from the Drugs Information Project
(“Geneesmiddelen Informatie Project” [GIP]), hosted by CVZ
[9]. Since 2006, the GIP comprises the health-care insurance data
for the whole of 16 million inhabitants of The Netherlands. Prior
to 2006, the data reﬂect the health-care insurance administration
of only 10 million persons, previously in the obligatory insurance
(“Ziekenfonds”). Cost-per-QALY estimates for those drugs that
were admitted to the GVS during the period 2005–2007 were
taken directly from the website of CVZ [1], and—according to
the Dutch procedure in this respect—reﬂect the manufacturer’s
calculations. In particular, such estimates could be found for
dorzalamid, erlotinib, fulvestrant, palivizumab, dasatinib, and
sitagliptin (see Table 1). Drugs with estimated negative costs
(savings) and equal or more QALYs compared with standard
treatment were not taken into the analyses, as those ﬁgures
would result in accepting the drug against any threshold (a recent
example of such a situation poses the submitted ﬁle for dabiga-
tran [1]).
Table 1 shows drug-speciﬁc reductions in the past Dutch
expenditures within the drugs budget had respective thresholds
been consistently and strictly applied. Depending on the exact
threshold considered, reduced expenditures vary from €32–33
million to a modest €2 million over the 3-year period considered
(approximately €0.1 to €2 per capita). Estimated reduced expen-
ditures were considerably higher in the last year of analysis at
€24,341,000 in 2007, than in the ﬁrst year considered with
€619,000 in 2005 (in this case evaluated at the threshold of
€20,000 per QALY). Annual drug-speciﬁc ﬁgures showed that all
drugs analyzed had reduced expenditures estimated in 2007.
Reduced expenditures were limited to 2007 only for dasatinib
and sitagliptin. For dorzalamid, erlotinib and palivizumab, part
of the reduced expenditures were estimated for 2006, although
consistently lower than for 2007 at 13%, 26%, and 16% of total
expenditures, respectively. For fulvestrant, estimated reduced
expenditures were distributed at 15% in 2005, 43% in 2006, and
42% in 2007.
With an average annual expenditure on outpatient drugs in
the period 2005–2007 of €4739 million, reductions in expendi-
tures as listed may be conceived as modest. In particular, at
thresholds of €0 and €20,000 estimated reductions in drug
expenditures reﬂect approximately 0.25% of total Dutch drug
expenditures and for thresholds of €50,000 and €80,000 this is
only 0.01%. These percentages were found to increase for any
next year, for example, from 0.01% in 2005 to almost 0.5% in
2007 for the lowest two thresholds.
Summary and Limitations
Our analysis suggests that modest, though annually increasing,
reductions in Dutch drug expenditures could have been achieved
in the recent period 2005–2007 had a formal threshold for
cost-effectiveness been applied in The Netherlands. During this
period, manufacturers of new innovative drugs had to ﬁle an
adequate cost-effectiveness analysis to have these respective
drugs eligible for reimbursement. In this respect “adequate”
meant that the analysis had to be performed according to the
guidelines for pharmacoeconomic research [10] and “common
sense” rules regarding transparency and levels of being evidence-
based. Adequacy of the pharmacoeconomic model is decisive for
reimbursement rather than the exact cost-effectiveness outcome.
Table 1 Drugs admitted to the Dutch Geneesmiddelenvergoedings-
systeem during 2005–2007, their estimated cost-effectiveness (CE) in
costs (€’s) per quality adjusted life year (QALY), reduced expenditures
(€’s) in the Dutch drugs budget during 2005–2007 had the respective
cost-per-QALY threshold been applied for denying reimbursement for
those drugs with an estimated CE surpassing this threshold
CE €0 €20,000 €50,000 €80,000
Dorzalamid 800 1,057,400 0 0 0
Erlotinib 37,000* 12,803,700 12,803,700 0 0
Fulvestrant 46,000 4,124,700 4,124,700 0 0
Palivizumab 49,000 13,479,900 13,479,900 0 0
Dasatinib 84,000 1,745,700 1,745,700 1,745,700 1,745,700
Sitagliptin 90,000 84,000 84,000 84,000 84,000
Total 33,295,400 32,238,000 1,829,700 1,829,700
*Per life-year gained.
854 Boersma et al.
As no formal threshold for cost-effectiveness is available in The
Netherlands, it currently remains unknown against which cost-
per-QALY to weigh individual drugs’ cost-effectiveness out-
comes. Regarding a formal threshold, €20,000 per QALY is
mostly mentioned in this respect. For example, for new vaccina-
tion programs, the Health Council explicitly mentions this ﬁgure
[11].
In particular, we found that drug expenditures could have
been reduced with up to approximately €30 million during the
period 2005–2007. At €20,000 per QALY, Dutch drug expendi-
tures would have been reduced by 0.5% in 2007. Such percent-
ages may be expected to even increase further in next years as
expenditures on these listed drugs may increase further and new
drugs with cost-effectiveness ratios above respective thresholds
may additionally be covered.
On the one hand, our quantiﬁcation of potential reductions in
drug budgets in relation to thresholds might be considered an
underestimate as all cost-per-QALY outcomes were derived from
manufacturers’ ﬁles. Obviously, such manufacturers’ analyses
might be biased toward favorable cost-effectiveness ratios [12]. If
cost-effectiveness analysis for new innovative drugs would be
required to be performed by independent parties not being spon-
sored by the pharmaceutical industries, such as universities and
national institutes, one may expect generally worse cost-
effectiveness ratios to be estimated. These higher ratios would
result in higher likelihoods for such drugs to surpass the thresh-
old. Also, as noted our data reﬂect an underestimation for the
year 2005 as the GIP database didn’t yet comprise the whole
Dutch population in that speciﬁc year.
On the other hand, our estimated reductions in the drugs
budget might represent overestimations as other drugs might
have been used as alternatives if the respective drugs had not
been reimbursed. For example, the use of docetaxel and pemetr-
exed might have been higher had less erlotinib been used in
recent years. Yet, as in other cases, no alternative would have
been available (palivizumab for respiratory syncytial virus) or
alternatives would be generically available and relatively cheap,
we would expect the overestimation to be limited.
Had indeed a threshold been applied during the period 2005–
2007, denial of some individual drugs would certainly have been
at the expense of QALY losses. Notably at €20,000 per QALY,
crudely evaluating on the numbers in Table 1 and neglecting
potential savings of drug use, maximally 733 QALYs would have
been lost had erlotinib, fulvestrant, palivizumab, dasatinib, and
sitagliptin not been used during the period considered. Stated
otherwise, minimally costs of €44,000 would have been saved for
each QALY lost. Obviously, these potential savings could have
been spend on other health-care interventions with cost-
effectiveness ratios under or closer to €20,000 per QALY. We do
realize that this spending could be hypothetical only, if the
approach to ﬁnancing health care would rather be from a more
restrictive than from a strict budgetary perspective.
We do note that despite the absence of a formal cost-
effectiveness threshold and the primarily qualitative assessment
of manufacturer’s cost-effectiveness analyses, the exact level of
the cost-effectiveness ratio might have contributed to individual
reimbursement decisions of speciﬁc drugs. It certainly could
inﬂuence the state of mind, and generally higher ratios tend to
discourage and lower to encourage reimbursement decision [13].
This might in particular have been tempting for those innovative
outpatient drugs exhibiting relatively high cost-effectiveness
ratios concomitantly with high budget impacts. In practice, this
has, however, not yet led to the denial of reimbursement for an
innovative outpatient drug with a methodologically adequate
cost-effectiveness analysis.
Toward a Formal Threshold in
The Netherlands?
Will we see a formal cost-effectiveness threshold to be adopted in
The Netherlands? Next to the obvious argument that deﬁnition
of such a threshold would enhance transparency of decision-
making, some further considerations are warranted in this
respect. A recent report analyses the pros and cons of a formal
threshold and the complexities how to assess or deﬁne it [14].
One major aspect to account for is that formal thresholds will
inﬂuence price setting of new drugs, which can both be in
upward and downward direction depending on the exact rela-
tions between such a threshold, international pricing of the
product and national pricing of its comparator(s). Obviously and
within the existing restrictions, manufacturers would price their
innovative products so as to be below, however, not far below,
any deﬁned cost-effectiveness threshold. Furthermore, it is
pointed out that strict application of cost-effectiveness thresholds
would not be in line with a primarily budgetary-oriented ﬁnanc-
ing of health care [14].
Despite the above, we would argue that for optimal and fair
allocation of resources in the health-care sector, application of
a straightforward threshold is eminent and should not be post-
poned anymore. Such a threshold though, would have to be
applied consistently over the whole health-care sector. With
cost-effectiveness assessments now thoroughly implemented in
drug assessments, however, not yet in various other sectors in
health care such as surgery and diagnostics, the danger exists
that reimbursement of drugs will be mostly and disproportion-
ately affected by the application of a threshold. Obviously, this
would hamper optimal allocation of resources in health care.
Therefore, next to pointing to the necessity of deﬁning a formal
threshold for cost-effectiveness, we point to the relevance of
consistently applying this to the whole spectrum of health-care
interventions, inclusive non-drug-type interventions. Of course,
next to such a threshold and the related cost-effectiveness per-
spective, other aspects should be noted in the decision-making
concerning reimbursement of new drugs, including equity,
affordability, continuity of care, characteristics of the disease
and the speciﬁc intervention at stake and the international
situation.
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